Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 53.62 as of 2026-10-06T21:58:26.646Z.
Consensus retrieved: 2026-10-06T17:14:28.216Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T21:58:26.646Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4326b808e448bd4143e63289af0f1314e4370c2287e91e713203ab21df88576c
Forward PE Ratio (53.62) = Dated Quote Price ($52.19) / Consensus Forward EPS ($0.97)
FORWARD PE RATIO
53.62
SECTOR MEDIAN · HEALTHCARE
19.75
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
+171.49%
vs the sector median at left
TG Therapeutics, Inc.
Market Cap
$7.99B
Forward PE Ratio
53.62
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| TG Therapeutics, Inc. (TGTX) | $7.99B | 53.62 |
| Praxis Precision Medicines, Inc. (PRAX)vs › | $7.81B | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $7.76B | 236.62 |
| Cytokinetics, Incorporated (CYTK)vs › | $7.63B | N/A |
| HealthEquity, Inc. (HQY)vs › | $7.61B | 19.27 |
| Hinge Health, Inc. (HNGE)vs › | $7.61B | 42.41 |
| Oscar Health, Inc. (OSCR)vs › | $8.38B | 16.94 |
| Ionis Pharmaceuticals, Inc. (IONS)vs › | $7.31B | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.67B | N/A |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.72B | N/A |
Trailing P/E
19.1
reported TTM EPS
Forward P/E
53.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $0.97 implies -64.6% EPS decline vs the reported trailing $2.74.
At the dated quote price of $52.19, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.97 | $0.74 – $1.40 | 5 | 53.6x |
| 2027-12-31 | $2.83 | $2.30 – $4.22 | 6 | 18.5x |
| 2028-12-31 | $3.62 | $3.14 – $4.21 | 6 | 14.4x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
